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Edited by Stuart FergusonAbstract The angiotensin II type I (AT1) receptor mediates
regulation of blood pressure and water-electrolyte balance by
Ang II. Substitution of Gly for Asn111 of the AT1 receptor con-
stitutively activates the receptor leading to Gq-coupled IP3 pro-
duction independent of Ang II binding. The Ang II-activated
conformation of the AT1N111G receptor was proposed to be sim-
ilar to that of the wild-type AT1 receptor, although, various as-
pects of the Ang II-induced conformation of this constitutively
active mutant receptor have not been systematically studied.
Here, we provide evidence that the conformation of the active
state of the wild-type and the constitutively active AT1 receptors
are diﬀerent. Upon Ang II binding an activated conformation of
the wild-type AT1 receptor activates G protein and recruits b-
arrestin. In contrast, the agonist-bound AT1N111G mutant recep-
tor preferentially couples to Gq and is inadequate in b-arrestin
recruitment.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The angiotensin II type I (AT1) receptor belongs to the G
protein-coupled receptor (GPCR) family and plays an impor-
tant role in blood pressure regulation and cardiomyocyte
growth [1,2]. The octapeptide hormone angiotensin II (Ang
II) binds to the AT1 receptor and generates diverse signals such
as intracellular production of inositol-1,4,5-triphosphates (IP3)
and activation of cytoplasmic kinases, mitogen-activated pro-
tein kinase, Src, and Rho [2]. Mutations of GPCRs, eitherAbbreviations: CAM, constitutively active mutant; IP3, inositol-1,4,5-
triphosphates; LH, luteinizing hormone
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doi:10.1016/j.febslet.2007.04.069found in humans or artiﬁcially generated, provide important
clues to the understanding of structure/function relationship
of the receptor [3]. Many of those mutations cause constitutive
activation of the receptor. Since the ﬁrst description of the con-
stitutive activity of a1-adrenergic receptor [4], constitutively
active mutations were found in several GPCRs from clinical
studies and provided valuable insights into the mechanisms
of GPCR activation [5]. Constitutively active mutants
(CAM) of human AT1 receptor are not yet reported presum-
ably due to its importance in regulating blood vessel constric-
tion during fetal growth. However, by site-directed
mutagenesis, a mutation of the residue Asn111 located in the
TM3 of the AT1 receptor, when substituted with a Gly was
shown to cause 40% increase of IP3 level in the absence of
the receptor agonist, Ang II [6]. The shorter the side chain of
amino acid residue substituted at the position of Asn111, the
greater the degree of constitutive activation [7].
The CAM receptors including the AT1N111G receptor are
considered to be mimicking the active conformations of the
wild-type receptors in that the mutations disrupt the constrain-
ing interactions between the TM domains. Activation of the
AT1 receptor requires loss of constraining interactions between
TM2 and TM7 [8,9]. Additional constraints have been sug-
gested, for instance between TM3 and TM7 [10–12]. These
conclusions are largely based upon experiments measuring
one or the other secondary messenger accumulation in the cell.
Such a comparison may be inadequate and may mask the po-
tential diﬀerence between agonist-activated conformation of
wild-type and CAM receptors. For instance, study on the
luteinizing hormone (LH) receptor showed that coupling of
the constitutively active mutant LHRD578G to cAMP produc-
tion is diﬀerent from that of the wild-type receptor when the
76 amino acid-long C-terminal peptide of the Gi2 protein
was co-expressed, suggesting that the two types of LH recep-
tors have distinct mechanisms of cAMP induction [13]. Unfor-
tunately, the agonist-induced active conformations of the
constitutively active GPCRs in terms of coupling to signaling
molecules other than heterotrimeric G proteins have not been
explored.
In the current study, we sought to elucidate the Ang II-in-
duced active conformations of the wild-type and the CAM
AT1 receptors with regards to coupling preferences to Gq
and b-arrestin 1 in COS-1 cells. We show that the Angblished by Elsevier B.V. All rights reserved.
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sequence on function, for instance calcium homeostasis.2. Materials and methods
2.1. Materials
The cDNA clone for human Gq-alpha dominant-negative mutant
(Q209L/D277N) was obtained from the UMR cDNA Resource Center
(www.cdna.org). [Sar1]Ang II was purchased from Bachem, Torrance,
CA. Monoclonal antibodies to HA and Gq were purchased from
Roche and Cell Signaling Technology, respectively. Monoclonal anti-
body to b-arrestin 2 (H-9) was purchased from Santa Cruz. Since this
anti-b-arrestin 2 antibody recognized both b-arrestin 1 and 2, we used
this antibody for the detection of transfected b-arrestin 1 in our exper-
iment. COS-1 cells are from American Type Culture Collection, Rock-
ville, MD. All other reagents unless stated otherwise were from Sigma.
2.2. Cell culture and expression of the AT1 receptor
The synthetic rat AT1 receptor gene, cloned in the shuttle expression
vector pMT3, was used for expression. Creation of the constitutively
active AT1 receptor mutant AT1N111G by site-directed mutagenesis
was described in a previous study [6]. To express the AT1 receptor pro-
tein with Gq or b-arrestin 1, 60–65% conﬂuent COS-1 cells grown in
10-cm petri dish were cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum. Cells were transfected with
10 lg of puriﬁed plasmid DNA using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions.2.3. Immunoprecipitations and Western blotting
Transfected cells were cultured for 48 h, treated with 1 lM [Sar1]An-
gII for 1 h, and then washed with cold PBS. Cells were scraped and
suspended in lysis buﬀer (25 mM HEPES, pH 7.2, 150 mM NaCl,
5 mM EDTA, 5 mM EGTA, 1% Triton X-100, 1 mM PMSF, 2 mM
AEBSF, 130 lM bestatin, 14 lM E-64, 1 lM leupeptin, 0.3 lM apro-
tinin, 25 mM b-glycerophosphate, 10 mM sodium ﬂuoride, 1 mM so-
dium orthovanadate, 10% glycerol) for 30 min. Cell lysates were
centrifuged at 13000 rpm for 10 min at 4 C to remove cell debris.
Anti-HA antibody was added to the supernatant with 20 ll of Protein
G-Sepharose (GE Healthcare) to immunoprecipitate the HA-AT1
receptors. After overnight incubation at 4 C on a rocker platform,
the immunoprecipitates were collected by centrifugation at
10000 rpm for 1 min at 4 C. Pellets were dissolved in Laemmli’s sam-
ple buﬀer, boiled for 5 min at 95 C, and separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis with a 10% separation gel.
Following electrophoresis the proteins were transferred to nitrocellu-
lose membranes and then blocked for 1 h at room temperature in
5% non-fat dry milk and 0.1% Tween-20 in PBS, pH 7.4. Incubation
with anti-Gq antibody or anti-b-arrestin antibody was carried out
overnight at 4 C. Following washes with PBS, incubation with horse-
radish peroxidase-conjugated secondary antibody was carried out for
1 h at room temperature. The detection was made with enhanced
chemiluminescence (GE Healthcare) and the ﬁlms were scanned for
densitometry analysis. Student’s t-test was used for statistical analysis
in Figs. 2 and 3.
2.4. Intracellular Ca2+ measurement
Changes in the cytoplasmic Ca2+ were measured using the ﬂuores-
cent calcium indicator dye Fura-2 (excitation max 340 nm and
380 nm, emission max 510 nm, Invitrogen). Transfected COS-1 cells
growing on cover glasses in a 6-well culture plate were loaded with
2 lM Fura-2 AM in BSS containing 0.1% Pluronic 127 and 2 mM
Ca2+ at 37 C for 30 min, followed by washing with BSS to remove
the extracellular dye. Calcium measurements were done in single cells
using an inverted microscope (Zeiss Axiovert 135) connected to a CCD
camera (Photon Technology International). The data were collected at
every 1.5 s interval and analyzed using the Image Master software
(Photon Technology International). The release of intracellular Ca2+
in individual cells was measured after exposure to 1 lM [Sar1]AngII
in a Ca2+-free balanced salt solution (BSS, 140 mM NaCl, 2.8 mM
KCl, 2 mM MgCl2, 0.5 mM EGTA, and 10 mM HEPES, pH 7.2) by
rapid solution exchange. Results are presented as average changes inthe ratio of Fura-2 ﬂuorescence upon excitation at 340 nm and
380 nm. Data from 6 to 8 cells were collected and plotted using Graph-
Pad Prism software.3. Results
3.1. Functional evidence for diﬀerence in Ang II-AT1WT and Ang
II-AT1N111G
To characterize the functional interaction of G-protein, Gq,
and b-arrestin 1 with AT1WT and AT1N111G receptors, we
examined Ang II-stimulated calcium release from intracellular
calcium store. The HA-tagged AT1WT and AT1N111G recep-
tors were expressed in COS-1 cells by transient transfection
of expression plasmids. The Ca2+-ﬂux was measured by single
cell imaging and the data were plotted (Fig. 1). The Ca2+-ﬂux
signal of AT1WT treated with Ang II was 1.4-fold compared to
baseline. The Ca2+-ﬂux signal of AT1N111G treated with Ang II
was 1.3-fold compared to its baseline. A simple explanation for
the lower Ca2+ response of the AT1N111G receptor could be
that the constitutive IP3 production causes constitutive de-
crease of the Ca2+ stores. However, similar to our ﬁnding, re-
duced Ca2+ response from Ang II-treated AT1N111G receptor
was reported previously by Auger-Messier et al. [14]. They
attributed the reduction to downregulation of the IP3 receptors
in HEK 293 cells and showed that the intracellular Ca2+ store
is intact [14].
In the next set of experiments, the HA-tagged AT1WT and
AT1N111G receptors were co-expressed with the dominant-neg-
ative mutant Gq (Q209L/D277N) and treated with 1 lM Ang
II. The amplitude of Ca2+-ﬂux signals was smaller in the pres-
ence of the dominant-negative Gq mutant than respective con-
trols. Interestingly, the onset of Ca2+-release upon Ang II
treatment was delayed (54.9 ± 0.6 s from the time of addition
of Ang II) for COS-1 cells expressing the AT1WT receptor
compared to the COS-1 cells expressing the AT1N111G mutant
receptor (24.3 ± 1.6 s) when dominant-negative mutant Gq
was expressed. This suggests that the dominant-negative Gq
was more eﬃcient in inhibiting the dynamic coupling between
Gq and AT1WT receptor than Gq and AT1N111G mutant
receptor.
It is well established that b-arrestin 1 is also a negative reg-
ulator of AT1 receptor coupling to Gq [15,16]. Therefore, to
test whether b-arrestin 1 over-expression inhibited Gq-medi-
ated Ca2+-signaling from the AT1 receptor, the AT1WT recep-
tor and AT1N111G was co-expressed with b-arrestin 1 in COS-1
cells. The mobilization of Ca2+ in cells with AT1WT receptor
co-expressed with b-arrestin 1 was completely blocked. Com-
pared to that the Ca2+ ﬂux in the AT1N111G co-expressed with
b-arrestin 1 was not completely abolished and furthermore the
onset of Ca2+ release was delayed. This observation suggested
that b-arrestin 1 prefers AT1WT rather than AT1N111G in the
presence of Ang II.3.2. Biochemical evidence for diﬀerence in Ang II-AT1WT and
Ang II-AT1N111G
To characterize the Ang II-induced conformational diﬀer-
ences between AT1WT and AT1N111G receptors in binding
the G protein and b-arrestin 1, we used receptor-Gq and recep-
tor-b-arrestin 1 pull-down assays. The HA-tagged AT1WT and
AT1N111G receptors were expressed in COS-1 cells with either
Fig. 1. Ca2+-mobilization from the AT1WT receptor and the constitutively active AT1N111G receptor when b-arrestin 1 and a dominant-negative Gq
(Q209L/D277N) was co-expressed, respectively. Delay of Ca2+-response from the AT1 receptor with GqDN or b-arrestin 1 was measured from the
time point Ang II was added to the medium to the highest peak of each Ca2+-response curve. Values are averages of 6–8 cells. Experiments were
repeated three times.
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complexes were precipitated by anti-HA antibody, separated
by SDS–PAGE, and transferred onto nitrocellulose mem-
brane. The amount of Gq protein coupled to the AT1WT or
AT1N111G mutant receptor were determined using anti-Gq
antibody (Fig. 2A). The result shows that equivalent amounts
of Gq are pre-coupled to the AT1WT receptor and the
AT1N111G mutant receptor. Although coupling to Gq is similar
under basal condition, upon ligand binding there is a 1.4-fold
(1.39 ± 0.23, P < 0.05) increase of Gq coupling to the
AT1N111G receptor whereas the amount of Gq coupled to
the AT1WT receptor remained constant. These results suggest
that the conformation of the AT1N111G is diﬀerent from that
of the AT1WT receptor in Gq-coupling. This observation is
consistent with a previous study by Auger-Messier et al. that
stimulation with Ang II stabilized the complex between the
CAM AT1N111G and Gq [17]. To test the expression level of
AT1 receptors in transfection, the nitrocellulose membrane
was stripped and reprobed with anti-HA antibody. The AT1
receptor expression level was similar as shown in Fig. 2B.
To study the coupling of b-arrestin 1 to the AT1WT or the
AT1N111G receptor, HA-tagged receptors were co-expressed
with b-arrestin 1 in COS-1 cells. Upon Ang II binding, con-
trary to what was observed for Gq coupling to the receptor,the amount of total b-arrestin 1 coupled to the AT1WT recep-
tor were increased 2.2-fold (2.23 ± 0.75, P < 0.05) whereas
there was 1.4-fold (1.41 ± 0.35, P < 0.05) increase of total b-
arrestin 1-coupling to the AT1N111Greceptor (Fig. 3A). A low-
er molecular weight band that reacting with anti-b-arrestin
antibody was found in the pull-down assay. This band seems
to be enhanced in cells expressing the AT1WT receptor treated
with Ang II. We interpret this ﬁnding as a potential proteolysis
event of b-arrestin 1 as has been described in the visual system
[18]. Next, the nitrocellulose membrane was stripped and re-
probed with anti-HA antibody to see the expression level of
the AT1 receptors in transfection. The overall expression level
of the AT1 receptors was similar among samples as shown in
Fig. 3B. The amount of receptor monomers increased upon
Ang II treatment in both AT1WT and AT1N111G receptors.
The coupling diﬀerence between the wild-type and CAM
AT1 receptors is unlikely to be due to diﬀerences in monomer
concentration. Increase in monomers upon receptor activation
has been shown for other GPCRs [19–21] and this may be the
case in AT1 receptor system also. These results clearly support
the idea that Ang II-activated conformation of the AT1WT
receptor preferentially recruits b-arrestin 1 but the agonist-
activated conformation of the AT1N111G receptor is deﬁcient
in this.
Fig. 2. Diﬀerences in Ang II-AT1WT and Ang II-AT1N111G for Gq-
coupling. (A) Wild-type or mutant HA-AT1 receptors were co-
expressed with Gq in COS-1 cells grown in 10-cm petri dish and
stimulated for 1 h with 1 lM [Sar1]AngII. Cells were lysed, immuno-
precipitated with 10 lg of anti-HA antibody followed by SDS–PAGE
and transferred onto nitrocellulose membrane. Gq-coupling to the AT1
receptors was determined by immunoblotting with anti-Gq antibody
(1:1000). Fold-increases were calculated compared to the wild-type
AT1 receptor without Ang II treatment. Data correspond to the
means ± S.D. from three independent experiments. A representative
blot is shown. (B) The nitrocellulose membrane was stripped with
western blot stripping buﬀer (Pierce) and re-blotted with anti-HA
antibody (1:1000) to see the amount of AT1 receptor expression.
Fig. 3. Diﬀerences in Ang II-AT1WT and Ang II-AT1N111G for b-
arrestin 1-coupling. (A) To see whether the coupling of b-arrestin 1
changes upon AT1 receptor activation, wild-type or mutant HA-AT1
receptors were co-expressed with b-arrestin 1 in COS-1 cells in 10-cm
petri dish and stimulated for 1 h with 1 lM [Sar1]AngII. Cell lysates
were immunoprecipitated with 10 lg of anti-HA antibody followed by
SDS–PAGE and transferred onto nitrocellulose membrane. b-Arrestin
1-coupling to the AT1 receptors were determined by immunoblotting
with anti-b-arrestin antibody (1:1000). Fold-increases were calculated
compared to wild-type AT1 receptor without Ang II treatment. Data
correspond to the means ± S.D. from three independent experiments.
A representative blot is shown. (B) The nitrocellulose membrane was
stripped with western blot stripping buﬀer (Pierce) and re-blotted with
anti-HA antibody (1:1000) to see the amount of AT1 receptor
expression.
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The experiments presented above elucidate a previously un-
known diﬀerence between Ang II-induced conformations of
the wild-type and the CAM AT1 receptors. Speciﬁcally, the
agonist-bound AT1N111G mutant diﬀers in recruiting b-arrestin
due to preferential association with the G protein, Gq. In pre-
vious studies these receptors were shown to eﬃciently activate
the Gq-phospholipase C pathway leading to nearly similar lev-
els of intracellular IP3 production [6–10,14]. However, Thomas
et al. demonstrated functional distinction in phosphorylation
between the active-state conformations of the AT1WT and
AT1N111G receptors [22]. Furthermore, Feng et al. demon-
strated functional distinction in desensitization and EGFR
trans-activation by AT1WT and AT1N111G receptors [23]. Thedata presented in this study clearly suggests that deactivation
of their agonist-activated states diﬀer. Hence the Ang II-in-
duced conformation of the AT1WT and the AT1N111G recep-
tors are diﬀerent and in each instance resulting in diﬀerence
in subsequent binding of intracellular proteins: the activated
state in the wild-type receptor traverses to interact with b-arr-
estin and in the AT1N111G receptor this transition is inept
resulting in its preferential coupling to Gq.
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basal activity and upon agonist binding the maximal activity
of the CAM receptors reach 80–100% of the wild-type recep-
tors. It was elucidated that the interactions between transmem-
brane domains are crucial in keeping the receptor in its inactive
R conformation and the CAM receptors achieve the active R*
conformation with higher probability in the absence of ago-
nists. Several models were suggested to explain the activation
mechanism of the CAM AT1 receptors [7,11,24]. Feng et al.
have shown that the substitution of Asn111 appears to release
the constraining intramolecular bonds between Asn111 and res-
idues in TM7 [7]. Le et al. have shown that Ang II binding to
the AT1WT receptor induces a pre-activated R
0 state of the
receptor and further conformational changes aﬀecting both
Ang II and the receptor shift the conformation to fully active
R* conformation [11]. Nikiforovich et al. have suggested that
the release of transmembrane interactions by substitutions of
Asn111 for other residues causes steric hindrance in other parts
of the AT1 receptor, and further releasing the constraints be-
comes a driving force for the activation of the AT1 receptor
[24]. However, upon agonist binding, the R* conformation
achieved in the wild-type and CAM receptors are considered
to be functionally identical (Fig. 4A). The results reported here
question adherence to this model in the case of agonist-bound
AT1WT and AT1N111G receptors (Fig. 4B).
A potential defect in the ability of the R* state of AT1N111G
mutant in transition to a phosphorylation-competent state was
suggested previously [22]. Our ﬁndings are consistent with this
suggestion, assuming that b-arrestin interaction with the AT1
receptor requires prior phosphorylation. Considering that G
proteins, GRKs, b-arrestins and other signaling molecules
compete for the overlapping binding sites on GPCRs, we
envisage a working model consisting of manifold R* states thatFig. 4. A model for ligand-induced conformations of the wild-type
and the constitutively active AT1receptors. (A) Based upon IP3
accumulation, the active conformation of the constitutively active
AT1N111G is considered to be similar to that of the agonist-induced
wild-type AT1 receptor. (B) Results from this study suggest that
agonist-induced conformations of the AT1WT and the constitutively
active AT1N111G receptors are diﬀerent in that the AT1WT receptor
traverses from the coupling of Gq to b-arrestin 1 upon agonist binding
whereas the constitutively active AT1N111G is inept in this transition
thus resulting to predominant Gq coupling.each favors recruitment of distinct signaling molecules. Hence,
it is worthwhile to investigate the active conformations of the
AT1N111G receptor with regards to coupling preferences to sig-
naling molecules other than heterotrimeric G proteins. Our
ﬁndings expand current understanding of the active-state con-
formation (R*) of the AT1 receptors not only to IP3 induction
via Gq coupling but also to the realm of b-arrestin coupling
(Fig. 4B). The ﬁndings reported by Feng et al. with regards
to unconventional desensitization could also be accounted
for by the model we suggest [23].
Our understanding of how diﬀerent types of ligands bind
and subsequently activate receptors is becoming more com-
plex. An increase in scientiﬁc sophistication has enabled us
to detect many diﬀerent types of receptor conformations
resulting from the binding of various ligands or sometimes
the same ligand. In the rhodopsin system, receptor activation
causes movements of TM3 and TM6 relative to each other
and may impart the proper conformation of the intracellular
loops for G protein activation [25–28]. This paradigm of
TM domain motion seems conserved in other GPCRs, espe-
cially the AT1 receptors [8,9,29] although some details may
diﬀer. Whether diﬀerences in these diﬀerent conformational
states translate into physiological reality is yet to be deter-
mined.
There are reasons to believe that the cellular consequence
and signaling pathways activated by the wild-type and the
CAM AT1 receptors may actually diﬀer. For instance, it has
been shown that b-arrestin recruitment by the activated wild-
type receptor is responsible for a distinct cytoplasmic phase
of ERK 1/2 activation, which is responsible for phosphoryla-
tion of cytoplasmic targets [30]. Although the signiﬁcance of
potential proteolysis of b-arrestin 1 reported in this study is
unclear, it is evident that the phenomenon is substantially re-
duced in the CAM AT1 receptor. A recent study shows that
there are morphological diﬀerences and Rho signaling impor-
tant for cytoskeletal change between HEK 293 cells expressing
the wild-type and the CAM AT1N111Greceptor [31]. Thus, the
AT1N111G mutant may serve as a useful research tool for the
understanding of exaggerated G protein signaling [32,33]. In
this regard, diﬀerent CAM receptors may actually diﬀer, and
well characterized CAM receptors may serve as important re-
search tools to understand beneﬁcial and/or harmful in vivo
consequence of select signals of the AT1 receptor. It is impor-
tant to characterize such diﬀerences between distinct signals
arising from receptors such as the AT1 receptor, where apart
from mutation induced eﬀects, the fragments of Ang II [34]
or Ang II-analogs used in therapy, could lead to manifold acti-
vated-states of the receptor in vivo.
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